Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cause of death

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,289 result(s) found for: Cause of death. Displaying page 1 of 165.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-002942-12 Sponsor Protocol Number: P04737 Start Date*: 2007-10-22
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Dis...
    Medical condition: Documented coronary artery disease, postischemic cerebrovascular disease or peripheral artery disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043634 Thrombosis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) NL (Completed) SE (Completed) PT (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) AT (Completed) DE (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-003519-23 Sponsor Protocol Number: D513BC00001 Start Date*: 2014-02-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Pat...
    Medical condition: major cardiovascular events in type 2 diabetes mellitus patients
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10042244 Stroke LLT
    19.1 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) NL (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed) NO (Completed) AT (Completed) DK (Completed) BE (Completed) FI (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000305-13 Sponsor Protocol Number: RIVAROXDVT3002/BAY59-7939/17261 Start Date*: 2014-07-07
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER)
    Medical condition: Prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Completed) CZ (Completed) IT (Completed) ES (Completed) NL (Completed) LT (Completed) BG (Completed) GR (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) PT (Completed) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003510-16 Sponsor Protocol Number: EFC15156 Start Date*: 2018-05-07
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabet...
    Medical condition: Cardiovascular diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) ES (Prematurely Ended) LV (Completed) LT (Completed) GB (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Completed) CZ (Prematurely Ended) DE (Completed) SK (Completed) HU (Completed) FI (Completed) PT (Completed) GR (Completed) PL (Completed) IE (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-005960-68 Sponsor Protocol Number: D9319C00001 Start Date*: 2021-07-24
    Sponsor Name:Astrazeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioi...
    Medical condition: Olaparib Maintenance Monotherapy in Participants with BRCAWild Type Ovarian Cancer Following Response toFirst-line Platinum-based Chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002644-32 Sponsor Protocol Number: EFC14875 Start Date*: 2017-11-14
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Ca...
    Medical condition: Type 2 diabetes mellitus Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) LV (Completed) GB (Completed) HU (Completed) SE (Completed) NO (Completed) FR (Completed) NL (Completed) DK (Completed) ES (Prematurely Ended) LT (Completed) EE (Completed) PT (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-002147-91 Sponsor Protocol Number: CV185-030 Start Date*: 2007-05-14
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalv...
    Medical condition: ARRHYTHMIA; THROMBOSIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    9.1 10057613 Thromboembolic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) BE (Completed) FI (Completed) ES (Completed) DK (Completed) HU (Completed) AT (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000671-25 Sponsor Protocol Number: 1242-001 Start Date*: 2016-09-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in S...
    Medical condition: Treatment of chronic heart failure with reduced ejection fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) DK (Completed) NL (Completed) FI (Completed) PL (Completed) BE (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000802-46 Sponsor Protocol Number: D169CC00001 Start Date*: 2018-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur...
    Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-004616-36 Sponsor Protocol Number: D5135C00001 Start Date*: 2013-02-04
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic str...
    Medical condition: peripheral artery disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10067825 Peripheral arterial disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) PL (Completed) GB (Completed) SE (Completed) ES (Completed) DE (Completed) HU (Completed) BG (Completed) CZ (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002513-35 Sponsor Protocol Number: CRLX030A3301 Start Date*: 2013-11-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.
    Medical condition: Acute heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BE (Completed) PT (Prematurely Ended) BG (Completed) LT (Completed) PL (Prematurely Ended) LV (Prematurely Ended) EE (Completed) FI (Prematurely Ended) SI (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) HR (Prematurely Ended) DK (Prematurely Ended) IS (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002019-16 Sponsor Protocol Number: U-2015-030 Start Date*: 2016-09-06
    Sponsor Name:Uppsala Clinical Research center
    Full Title: Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction
    Medical condition: Heart Failure with Preserved Ejection Fraction, HFPEF
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000664-31 Sponsor Protocol Number: D169DC00001 Start Date*: 2020-08-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Ac...
    Medical condition: Acute Myocardial Infarction, Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-002004-24 Sponsor Protocol Number: CV185-316 Start Date*: 2017-02-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillatio...
    Medical condition: Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    20.0 10042613 - Surgical and medical procedures 10065608 Percutaneous coronary intervention PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BG (Completed) AT (Completed) BE (Completed) DK (Completed) NL (Completed) PL (Completed) PT (Completed) ES (Completed) CZ (Completed) DE (Completed) SE (Completed) SK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000334-17 Sponsor Protocol Number: TRACK_001 Start Date*: 2023-03-31
    Sponsor Name:The George Institute of Global Health
    Full Title: Treatment of cardiovascular disease with low Rivaroxaban in Advanced Chronic Kidney Disease - TRACK trial
    Medical condition: Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002893-38 Sponsor Protocol Number: CA209-8PA Start Date*: 2019-03-05
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Phase II Study on NIVolumab in combination with FOLFOXIRI/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer RASm/BRAFm patients
    Medical condition: Advanced colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003268-25 Sponsor Protocol Number: AT-03A-017 Start Date*: 2023-05-12
    Sponsor Name:Atea Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001498-25 Sponsor Protocol Number: CRLX030A2301 Start Date*: 2013-09-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure pa...
    Medical condition: Acute heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SE (Completed) IE (Completed) BG (Completed) HU (Completed) PT (Completed) LT (Prematurely Ended) IT (Completed) CZ (Completed) AT (Completed) EE (Completed) DK (Completed) ES (Completed) LV (Prematurely Ended) NL (Completed) GR (Completed) GB (Completed) PL (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2016-003930-26 Sponsor Protocol Number: DU-176B-C-U4001 Start Date*: 2017-05-15
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation – In Atrial Fibrillation. ENVISAGE-TAVI AF
    Medical condition: Patients with atrial fibrillation (AF) and indication to chronic oral anticoagulant after transcatheter aortic valve implantation (TAVI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004338-42 Sponsor Protocol Number: CV185-023 Start Date*: 2006-06-24
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban In Patients with a Recent Acute Coronary Syndrome. Revised Pr...
    Medical condition: ACUTE CORONARY SYNDROMES,NOS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed) ES (Completed) BE (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 29 13:24:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA